Regeneron Pharmaceuticals Inc (REGN)

477.15
NASDAQ : Health Care
Prev Close 477.15
Day Low/High 0.00 / 0.00
52 Wk Low/High 325.35 / 543.55
Avg Volume 879.80K
Exchange NASDAQ
Shares Outstanding 107.15M
Market Cap 51.29B
EPS 6.20
P/E Ratio 48.01
Div & Yield N.A. (N.A)

Latest News

The New #48 Most Shorted Nasdaq 100 Component: Regeneron Pharmaceuticals

The most recent short interest data has been released for the 07/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Stock prices are either unfairly dragged down by competitors' earnings news or by Amazon's spread into more businesses, Cramer said.

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Game on: Jim Cramer is bullish on Electronic Arts, Activision Blizzard and Take-Two Interactive.

Cramer: Rotations Hit Companies That Don't Deserve It

Cramer: Rotations Hit Companies That Don't Deserve It

Case in point: Home Depot and Lowe's.

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Oracle Re-rating; No Country for Old Value: Jim Cramer's View

Oracle Re-rating; No Country for Old Value: Jim Cramer's View

Cramer shares his views on Oracle's re-rating and also discusses the constant battle between growth and value.

How President Trump Has Sent Biotech Stocks Soaring

How President Trump Has Sent Biotech Stocks Soaring

The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.

Biotech Movers: Regeneron Slides Back After Big Gains

Biotech Movers: Regeneron Slides Back After Big Gains

The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.

Cramer: Stop Talking About the 'Market'

Cramer: Stop Talking About the 'Market'

It just isn't as useful or descriptive right now.

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day

Healthcare leads markets after the release of the Senate health plan.

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill

Healthcare leads markets after the release of the Senate health plan.

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare Leads as Stocks Turn Higher After Release of Senate Bill

Healthcare leads markets after Senate bill's release.

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Growth is crushing value, says Jim Cramer, and the dynamic is more pronounced in individual sectors.

Cramer: This Is No Country for Old Value

Cramer: This Is No Country for Old Value

Down-and-out stocks have become toxic.

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data

Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.

9 Incredible Jobs That Let You Travel For Free

9 Incredible Jobs That Let You Travel For Free

Traveling can be a life-changing event, but it's often costly.

Cramer: You Need 2 Monday Morning Game Plans

Cramer: You Need 2 Monday Morning Game Plans

We really want to shake out the weak hands here.

Inovio Pharmaceuticals: Cramer's Top Takeaways

Inovio Pharmaceuticals: Cramer's Top Takeaways

Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.

Amgen Wants to Boost Label on Powerhouse Repatha

Amgen Wants to Boost Label on Powerhouse Repatha

The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog

Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.

Cramer: Rally Is Earning Some Trust

Cramer: Rally Is Earning Some Trust

The market rally broadened out nicely today.

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

Alexion Pharma: Negative Market Sentiment Creates Buying Opportunity

I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.

Charting the Biotechs

Charting the Biotechs

Time to revisit some stocks now that biotech has cooled.

The New #233 Most Shorted S&P 500 Component: Regeneron Pharmaceuticals

The most recent short interest data has been released for the 04/28/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.